MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Bluebird Bio Inc

Cerrado

4.92 -5.02

Resumen

Variación precio

24h

Actual

Mínimo

4.79

Máximo

5.35

Métricas clave

By Trading Economics

Ingresos

32M

-29M

Ventas

28M

39M

BPA

-2.84

Margen de beneficios

-74.536

Empleados

248

EBITDA

20M

-40M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 Meses

+29.22% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

9.6M

48M

Apertura anterior

9.94

Cierre anterior

4.92

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Bluebird Bio Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

26 sept 2024, 16:08 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Pfizer's Strategy Looks Shakier After Sickle-Cell Disappointment -- Barrons.com

Comparación entre iguales

Cambio de precio

Bluebird Bio Inc previsión

Precio Objetivo

By TipRanks

29.22% repunte

Estimación a 12 Meses

Media 6.5 USD  29.22%

Máximo 8 USD

Mínimo 5 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Bluebird Bio Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

5 ratings

1

Comprar

4

Mantener

0

Vender

Puntuación técnica

By Trading Central

3.72 / 3.82Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

No Evidence

Largo Plazo

No Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Bluebird Bio Inc

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.